3
Participants
Start Date
July 31, 2009
Primary Completion Date
May 31, 2012
Study Completion Date
April 30, 2027
autologous or syngeneic PBTLs and EBV-CTLs
"Three dose levels are being evaluated namely:~GROUP 1~PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2~GROUP 2~PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2~GROUP 3~PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
Houston Methodist Hospital, Houston
Texas Children's Hospital, Houston
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
The Methodist Hospital Research Institute
OTHER
Baylor College of Medicine
OTHER